Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Gilead Sciences, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META or NKE, where it is open to everyone.
GILD · Nasdaq · ·
Next earnings: October 29, 2026
$151.30-0.6%Sep 29 close
Gilead sells medicines for human immunodeficiency virus, liver disease, cancer, and coronavirus disease 2019.